Heart Attack

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™

HeartRisk™ Empowers Employers Who Adopt Cardio Diagnostics’ Solutions to Proactively Combat Cardiovascular Disease in Their Workforce and Mitigate Business RisksCHICAGO--(BUSINESS…

11 months ago

Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea

-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive…

11 months ago

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

Atherosclerosis, an inflammatory disease characterized by buildup of cholesterol, lipids, and other substances (plaque) in arteries leading to heart attack…

12 months ago

American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc’s Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes

CPT codes are critical to receiving reimbursement from federal and private payersCHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader…

12 months ago

PMcardio Is The First Certified Solution To Outperform Doctors in Heart Attack Detection With AI

PMcardio Queen of Hearts PMcardio's Queen of Hearts AI model is the first certified solution to outperform doctors in heart…

1 year ago

Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine

Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated…

1 year ago

Elucid Raises $80 Million in Series C Round Led by Elevage Medical Technologies

Investment will drive commercialization and expansion of AI-powered non-invasive diagnostic tools to help evaluate cardiovascular riskBOSTON--(BUSINESS WIRE)--Elucid, a leading medical…

1 year ago